Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Current Deferred Revenue (2019 - 2022)

Aethlon Medical filings provide 4 years of Current Deferred Revenue readings, the most recent being $574245.0 for Q4 2022.

  • On a quarterly basis, Current Deferred Revenue rose 150.0% to $574245.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $574245.0, a 150.0% increase, with the full-year FY2022 number at $344547.0, up 200.0% from a year prior.
  • Current Deferred Revenue hit $574245.0 in Q4 2022 for Aethlon Medical, roughly flat from $574245.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $574245.0 in Q3 2022 to a low of $100000.0 in Q3 2019.
  • Median Current Deferred Revenue over the past 4 years was $229698.0 (2021), compared with a mean of $280033.0.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 407.02% in 2020 and later crashed 77.35% in 2021.
  • Aethlon Medical's Current Deferred Revenue stood at $100000.0 in 2019, then skyrocketed by 407.02% to $507022.0 in 2020, then tumbled by 54.7% to $229698.0 in 2021, then surged by 150.0% to $574245.0 in 2022.
  • The last three reported values for Current Deferred Revenue were $574245.0 (Q4 2022), $574245.0 (Q3 2022), and $459396.0 (Q2 2022) per Business Quant data.